Oxford Biomedica PLC R&D Partnership with Green Cross LabCell (0223A)
June 02 2016 - 4:05AM
UK Regulatory
TIDMOXB
RNS Number : 0223A
Oxford Biomedica PLC
02 June 2016
Oxford BioMedica and Green Cross LabCell form a Partnership to
Develop Gene-modified NK Cell Therapeutics in cancer
Unique combination of Oxford BioMedica's LentiVector(R) delivery
platform and Green Cross LabCell's NK cell platform to generate a
pipeline of differentiated products in cancer
Oxford, UK & Seoul, Korea - 2 June 2016: Oxford BioMedica
plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene
and cell therapy group, today announces that it has entered into a
Research & Development Collaboration with Green Cross LabCell
("GCLC"), a subsidiary of Green Cross Holdings, a leading South
Korean biopharmaceutical company that delivers life-saving and
life-sustaining protein therapeutics and vaccines. The
collaboration will focus on identifying and developing gene
modified natural killer (NK) cell-based therapeutics for treatment
of life-threatening diseases such as cancer.
This collaboration brings together two clinically validated
platform technologies with the aim of generating a pipeline of
novel and differentiated cell-based products in areas of serious
unmet medical need. Oxford BioMedica is contributing its clinically
tested LentiVector(R) gene delivery platform for the efficient
modification of immune cells, as well as its expertise in GMP
bioprocessing, clinical development and regulatory affairs in ex
vivo cell & gene therapy. GCLC is contributing its clinically
tested platform for production of highly potent and activated NK
cells.
During the initial Research Collaboration, Oxford BioMedica and
GCLC (the "Parties") will collaborate to identify potential NK
cell-based product candidates, modified using lentiviral vectors.
The collaboration will focus on allogeneic CAR-NK cell-based
products. Under the terms of the agreement, Oxford BioMedica and
GCLC will share the costs associated with the Research
Collaboration equally. Oxford BioMedica's contribution to the
Research Collaboration will be funded from its existing Discovery
resources and budget. The Parties will agree which product
candidates from the Research Collaboration will be taken forward
into the Development Collaboration stage of the programme on a
product-by-product basis.
After nearly a decade of research on NK cells, GCLC has gathered
a substantial body of evidence that their proprietary manufacturing
platform for activated NK cells derived from peripheral blood
mononuclear cells (PBMCs), such as MG4101, has potential to act as
the basis for a pipeline of CAR-NK and other gene-modified NK cell
products. By forming a partnership with GCLC, Oxford BioMedica
gains access to one of the leading, clinically validated NK cell
platforms in the industry and access to a highly skilled and
experienced R&D partner in Korea, one of the most dynamic
biotechnology markets in Asia.
Commenting on the new partnership, John Dawson, CEO of Oxford
BioMedica, said: "We are very excited to form a key partnership
with Green Cross LabCell, who have the industry-leading production
platform for NK cell therapeutics for cancer. Over the years Green
Cross LabCell has built a significant depth of scientific,
technical and industrial expertise in NK cells that is difficult to
find elsewhere.
"We are therefore delighted to be collaborating with Green Cross
LabCell in a new partnership which brings our LentiVector(R)
delivery platform and expertise to the relationship and which
builds on our existing partnerships with other companies including
Novartis, Sanofi, GSK and Immune Design. We believe that our
collaboration will lead to the generation of a rich pipeline of
novel gene-modified NK cell therapeutics for both companies."
Bok-Soo Park, Chief Executive Officer of Green Cross LabCell,
commented "To work with Oxford BioMedica as our partner for the
development and future commercialization of gene-modified NK cell
products is exciting, given their world-leading expertise in the
clinical development and bioprocessing of lentiviral vector based
products. This agreement underscores our commitment to maximise the
value of our technologies and accelerate their progress to the
market through partnering with industry leaders. We chose to work
with Oxford BioMedica as we believe they are best positioned to
accelerate development of these programs and are fully committed to
their success. We look forward to working with the team at Oxford
BioMedica to bring desperately needed new treatment options to
cancer to patients all around the world."
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Financial and corporate communications Tel: +44 (0)20
enquires 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris
Welsh/Laura Thornton
Green Cross LabCell: Tel: +82 (0)31
Bok-Soo Park, Chief Executive Officer 260 0834
Yu-Kyeong Hwang, Chief Technology
Officer
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R)) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
230 people. Further information is available at
www.oxfordbiomedica.co.uk.
About Green Cross LabCell
Green Cross LabCell is a subsidiary of Green Cross Corp, a
leading Korean pharmaceutical company with its headquarters in
Seoul. Green Cross Corp. has annual sales of more than $1 billion
across 14 marketed prescription products. The Company has been
actively developing a number of new technologies and products in
the emerging cell therapy industry. Its subsidiary, Green Cross
LabCell is focused on clinical development of MG4101, a random
donor PBMC-derived, ex vivo expanded and activated NK cell product
in a number of Phase II clinical trials in Korea, as well as
developing next generation gene-modified NK cell therapeutics.
Green Cross LabCell operates its own GMP facilities in Seoul, Korea
for production of NK cell based therapeutics. Its proprietary
production platform enables allogeneic supply of therapeutic NK
cells for multiple clinical trials. This technology platform holds
the promise to dramatically reduce the cost of gene-modified cell
therapies for cancer, while also aiding the quality control and
industrial scale production of NK cell products.
About Oxford BioMedica's LentiVector(R) Delivery Platform
Oxford BioMedica has developed one of the most clinically
validated gene therapy delivery systems based on lentiviruses. Its
LentiVector(R) platform has been tested in more than 60 patients in
clinical trials focussing on CNS and ophthalmology applications. In
addition, via the Company's collaboration with Novartis in the
field of CAR-T therapeutics, its vectors have been broadly used in
the ex vivo setting for treating severe unmet medical needs in
cancer.
About MG4101
MG4101 is a clinical stage cell-based product developed by Green
Cross LabCell based on ex vivo expanded and activated NK cells
derived from peripheral blood mononuclear cells from random healthy
donors. MG4101 has completed a Phase I study in patients with a
variety of terminal stage solid tumours and recurrent lymphoma
patients (NCT01212341, Cancer Immunol Res. 2016 Mar;4(3):215-24.),
a Phase II study in hepatocellular carcinoma (HCC) after resection
(NCT02008929), and a Phase II study in paediatric solid tumours
(NCT01807468). Another Phase II study in HCC after transarterial
chemoembolization (TACE) will be start in Q3 2016. MG4101 and its
associated production process provide the basis for the next
generation of gene-modified NK cell therapeutics being jointly
developed by Green Cross LabCell and Oxford BioMedica.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFTMLTMBMMMJF
(END) Dow Jones Newswires
June 02, 2016 05:05 ET (09:05 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024